Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Donya Shahamati, MS | Image Credit: LinkedIn

The Planetary Health Diet is associated with a lower risk of overall cardiovascular disease, 

 among postmenopausal women, according to the results of a 20-year study.

The Planetary Health Diet, created by the EAT-

 Commission in 2026, is designed to optimize human health without sacrificing the earth’s environment. The diet is structured with an expected future population of 10 billion people – to protect land and nutrition access, the diet is flexible and sustainable, focusing on whole plant foods, healthy fats, and very low amounts of animal products.

“Our results suggest that people may not need to follow a perfect or very restrictive diet to see potential heart-health benefits,” Donya Shahamati, MS, a doctoral student in public health at the University of California, Irvine, said in a statement. “This is especially important for postmenopausal women, because cardiovascular risk increases with age and tends to rise after menopause.”

Shahamati and colleagues analyzed data from the Women’s Health Initiative Observational Study (WHI-OS), a prospective cohort of postmenopausal women in the US. Among the women in this program, the team enrolled those with complete baseline dietary data and follow-up information through February 2025. Patients with known cardiovascular disease at baseline, implausible total energy intake, or missing dietary data or follow-up time, were excluded.

The team utilized mean Planetary Health Diet Index (PHDI) as the main exposure, which was calculated via dietary intake reported on the WHI food frequency questionnaire. The team examined PHDI as both quintiles and a continuous score. These data were used to represent each patient’s alignment with the EAT-

 dietary recommendations. The study’s primary outcome was incident total cardiovascular disease, defined as the first occurrence of CHD, stroke, or HF. Secondary outcomes included CHD, stroke, ischemic stroke, hemorrhagic stroke, and HF.

A total of 66,892 postmenopausal women were included in the analytic sample. Baseline PHDI scores ranged from 35-123 (mean +/- SD [standard deviation]; 75.5 +/- 10.3). Mean PHDI scores increased across all quintiles, from roughly 61 in Q1 to 90 in Q5.

How the Diet Changed Cardiovascular Outcomes

Over a median of 19.6 years (interquartile range [IQR], 8.9-26.8), 5033 incident total cardiovascular disease events occurred. Crude incidence rates decreased across all PHDI quintiles for most outcomes; after adjusting for covariates, Shahamati and colleagues found that higher PHDI scores were associated with lower hazards of most cardiovascular disease outcomes. Total cardiovascular disease saw lower hazards from Q2 through Q5 compared with Q1 (Q2 HR, 0.86; 95% CI, 0.78-0.95; Q5 HR, 0.72; 95% CI, 0.64-0.81; 

-trend <.001). This pattern remained consistent for CHD, stroke, ischemic stroke, and HF. For each 10-point higher PHDI score, the hazard was lower for total cardiovascular disease, CHD, stroke, ischemic stroke, and HF. The team did not find a statistically significant association with hemorrhagic stroke.

Ultimately, Shahamati and colleagues determined that women in the highest PHDI quintile had a 28% lower hazard of total cardiovascular disease versus those in the lowest quintile over long-term follow-up. The team noted that these findings are generally consistent with prior longitudinal cohort studies, which found inverse associations between PHDI scores and cardiovascular disease outcomes in other populations.

“Moving to a more plant-forward, higher-quality diet can be accomplished through small, realistic changes,” Shahamati said in a statement. “These changes might include filling half the plate with vegetables more often; using avocado or olive oil in place of butter; choosing oatmeal or whole-grain cereal for breakfast; or trying a meatless meal once per week.”

American Society for Nutrition. Plant-forward planetary health diet linked to lower heart disease risk. 

https://www.eurekalert.org/news-releases/1136409

Roeder A. Planetary Health Diet: Better for you, better for the planet. 

. September 12, 2024. Accessed July 31, 2026. 

https://hsph.harvard.edu/news/planetary-health-diet-better-for-you-better-for-the-planet/

Shahamati D, Yang B, Liu S, et al. Association between the Planetary Health Diet Index and risk of cardiovascular diseases in postmenopausal women: Findings from the Women’s Health Initiative Observational Study. American Journal of Preventive Cardiology. Published online July 17, 2026:101750. 

Articles

Higher adherence to the EAT-Lancet Planetary Health Diet among US postmenopausal women was associated with lower long-term risk of incident cardiovascular disease, including CHD, stroke, ischemic stroke, and heart failure. In the WHI-OS cohort followed for a median of 19.6 years, increasing Planetary Health Diet Index (PHDI) scores showed a graded inverse relationship with major cardiovascular outcomes after multivariable adjustment. The highest PHDI quintile demonstrated a 28% lower hazard of total cardiovascular disease versus the lowest, while no significant association emerged for hemorrhagic stroke.

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Structural Heart Disease

Planetary Health Diet Reduces Risk of Cardiovascular Disease, CHD, Stroke, HF

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Pooled data from the phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials showed nerandomilast (Jascayd) reduced the risk of death by 33% at the 9 mg twice-daily dose and by 43% at the 18 mg twice-daily dose compared with placebo in patients with idiopathic 

 (IPF) and progressive pulmonary fibrosis (PPF), according to results published in the 

Nerandomilast, a preferential phosphodiesterase 4B (PDE4B) inhibitor, received its first regulatory approvals for IPF and PPF based on the FIBRONEER trials, in which both doses reduced the primary endpoint of forced vital capacity (FVC) decline at week 52 versus placebo.

 The key secondary composite endpoint, time to first acute exacerbation, respiratory hospitalization, or death, was not met in either trial at the first database lock, meaning downstream analyses of individual components, including mortality, are considered exploratory.

 Because hierarchical testing stopped once the composite endpoint missed significance, all mortality p-values reported are nominal rather than confirmatory.

Justin M Oldham, MD, Clinical Associate Professor, University of Michigan Health, and colleagues wrote that “over the whole trial, there was a numerical reduction of 34% in the risk of death with nerandomilast 18 mg bid versus placebo in FIBRONEER-IPF and a nominally significant reduction in the risk of death of 49% with both doses of nerandomilast versus placebo in FIBRONEER-ILD. We performed additional analyses to investigate the effect of nerandomilast on mortality in the FIBRONEER trials.”

What Did Pooled Survival Data From FIBRONEER Trials Show?

The analysis pooled data from FIBRONEER-IPF and FIBRONEER-ILD, in which patients with IPF or an ILD other than IPF with a progressive fibrosing phenotype were randomized 1:1:1 to nerandomilast 9 mg twice daily, 18 mg twice daily, or placebo.

 Across both trials, 2353 patients received at least 1 dose of trial medication, with mean exposure of approximately 15 months and mean observation time of approximately 17 months.

 The primary analysis of time to death used a Cox proportional hazards model adjusted for background antifibrotic therapy, age, and lung function, based on all deaths except those after lung transplant.

In the pooled analysis, deaths occurred in 106 patients (13.5%) on placebo, 72 patients (9.2%) on nerandomilast 9 mg twice daily (HR, 0.67; 95% CI, 0.49-0.90; 

= .009), and 60 patients (7.7%) on nerandomilast 18 mg twice daily (HR, 0.57; 95% CI, 0.41-0.78; 

 The mortality benefit reached significance in FIBRONEER-ILD alone, where both doses reduced the hazard ratio to 0.51 (95% CI, 0.34-0.78) versus placebo, but not in FIBRONEER-IPF alone, where the hazard ratio for the 18 mg dose was 0.66 (95% CI, 0.41-1.08).

 The number needed to treat with the 18 mg dose to prevent 1 death over a median exposure of approximately 16.5 months was 13 in FIBRONEER-ILD and 43 in FIBRONEER-IPF.

Is nerandomilast approved for pulmonary fibrosis?

Yes; nerandomilast (Jascayd) is FDA-approved for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), based on FVC decline data from the FIBRONEER trials; the mortality findings in this analysis were exploratory and were not part of the approval basis.

Nerandomilast is a preferential phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic, immunomodulatory, and vascular effects thought to reduce pro-fibrotic and pro-inflammatory signaling in the lung.

What did the pooled FIBRONEER mortality analysis show?

Pooled data from FIBRONEER-IPF and FIBRONEER-ILD showed nerandomilast reduced the risk of death by 33% at 9 mg twice daily and 43% at 18 mg twice daily versus placebo, with sensitivity and tipping-point analyses supporting the robustness of the finding despite its post hoc, exploratory nature.

What Was Nerandomilast Dosing and Analysis Limitations?

Sensitivity analyses adjusting for additional covariates and supplementary analyses censoring deaths at various points after treatment discontinuation were consistent with the primary mortality findings.

 Two tipping-point analyses found the mortality benefit would only lose statistical significance under extreme, implausible assumptions about missing vital-status data, such as an 8% yearly mortality rate in the placebo group with missing data rising to 78% in the nerandomilast 18 mg missing-data group before the effect disappeared.

 In FIBRONEER-ILD, no significant treatment-by-subgroup interaction was found across ILD diagnoses, though small numbers of deaths in each subgroup produced wide, overlapping confidence intervals.

Exposure-response analyses found higher trough plasma concentrations of nerandomilast were associated with a lower risk of death, with median exposure roughly twice as high at the 18 mg dose as the 9 mg dose.

 The study authors noted patients taking background pirfenidone should not use the 9 mg twice-daily dose, since a drug interaction reduces nerandomilast plasma levels by approximately 50% and renders the 9 mg dose ineffective in this population.

 The trials were not powered to assess mortality as an endpoint, and the study authors noted all analyses besides the primary time-to-death analysis were conducted post hoc.

Nerandomilast received FDA approval for IPF in October 2025 and for PPF in December 2025, based on the FVC data from the FIBRONEER trials rather than the mortality analyses reported here.

 The study authors called for further research into the drivers of mortality in pulmonary fibrosis and the mechanisms behind nerandomilast's survival signal.

Oldham JM, Assassi S, Azuma A, et al. Effect of nerandomilast on survival in patients with pulmonary fibrosis. Eur Respir J. 2026; in press. doi:10.1183/13993003.00338-2026

FDA approves new treatment option for adults with PPF. Boehringer Ingelheim. Published December 2025. Accessed July 30, 2026. https://www.boehringer-ingelheim.com/us/human-health/lung-diseases/pulmonary-fibrosis/fda-approves-new-treatment-option-adults-ppf

Pooled survival analyses from phase 3 FIBRONEER-IPF and FIBRONEER-ILD suggest nerandomilast, a preferential PDE4B inhibitor, is associated with dose-dependent reductions in all-cause mortality versus placebo over ~17 months’ observation. Adjusted Cox modeling showed HR 0.67 with 9 mg bid and 0.57 with 18 mg bid, with a clearer signal in PPF (FIBRONEER-ILD) than IPF alone. Interpretation is constrained by hierarchical testing failure of a key secondary composite endpoint, rendering mortality results nominal and exploratory.

Pooled FIBRONEER trial data show nerandomilast reduced the risk of death by up to 43% versus placebo, though the analysis was post hoc.

Pulmonary Fibrosis

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Nerandomilast Reduces Mortality Risk in Pulmonary Fibrosis Analysis

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

Recent trial data have broadened the case for GLP-1 receptor agonists in kidney disease, pointing to a possible role beyond the drug class's original diabetes indication. 

Translating that evidence into everyday practice hasn't necessarily kept pace, says Pranav Garimella, MD, chief medical officer at the American Kidney Fund, who points to cost, clinician unfamiliarity, and gaps in patient identification as ongoing barriers to access.

GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy

What Does the Evidence Show for GLP-1 Receptor Agonists in Kidney Disease?

 In more than 3,500 participants with type 2 diabetes and CKD, semaglutide cut kidney-specific outcomes by 21% and slowed annual eGFR decline versus placebo.[1]

 A 22% reduction in the composite kidney endpoint among non-diabetic participants with cardiovascular disease and obesity.[1]

 Semaglutide cut a marker of kidney protein loss by roughly half over 24 weeks in people with overweight or obesity.[1]

"GLP-1 [receptor agonists] no longer belong just in the treatment of diabetes," Garimella has said, describing them as integral to preventing both heart failure and kidney disease progression. He frames them as complementary to RAS inhibitors, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists (MRAs)—and, in select patients without significant proteinuria who have obesity, sleep apnea, or elevated heart failure risk, as a potential alternative to nonsteroidal MRAs. His approach broadly tracks the 2024 KDIGO CKD guideline, which pairs RAS/SGLT2 inhibitor therapy with emerging support for nonsteroidal MRAs and GLP-1 receptor agonists.

What Barriers Limit GLP-1 Receptor Agonist Use in Kidney Disease?

Garimella pointed to four first-line barriers still limiting access:

 "The ability to get these for all patients across all payers remains a challenge," he told HCPLive, noting that coverage criteria can differ by indication—diabetic kidney disease, heart failure, or obesity—so documenting the specific indication at prescribing matters.

 GLP-1s were historically viewed as diabetes-only drugs prescribed mainly by primary care and endocrinology. "Now we know that these medications can prevent kidney disease progression [and] heart disease progression, and so cardiologists and nephrologists are using them more often," Garimella said.

 Clinicians need to correctly flag patients with CKD alongside diabetes, obesity, or heart failure—including as a complementary option for patients who need to come off a drug class that's raising their potassium levels.

 Not every patient tolerates the maximal dose. "We may need to back off to the best-tolerated dose, or even take patients off of it," Garimella said, adding that setting this expectation early keeps patients on therapy long enough to see benefit.

How Should Clinicians Discuss Weight Loss With GLP-1 Patients?

Garimella pushes back on the stigma that can surround weight-loss discussions in clinic. Central adiposity drives cardiac, kidney, and metabolic dysfunction, he said, so he frames GLP-1 therapy around long-term outcomes rather than the scale: "I show patients that this is doing more than just changing the numbers on the scale... The overarching goal is to connect that medication with the outcomes—not just the weight loss in the short term, but really those long-term outcomes that we're trying to prevent."

What's Next for GLP-1 Receptor Agonists in Kidney Disease?

GLP-1 receptor agonists are approaching standard therapy in the CKD toolkit, Garimella said, with wider use across disease states and combination therapies likely as data accumulates and FDA indications expand. Open questions remain: which patients benefit most versus those where risk outweighs benefit, how long therapy should continue, and how to manage patients who regain weight after stopping. Evidence is also thin in medically complex populations. "We don't know what the true benefits of GLP-1 receptor agonists are in patients who've received kidney transplants," he said, noting many still have diabetes, proteinuria, obesity, heart failure, or sleep apnea. "That is an area that is ripe for research still in the GLP-1 space."

: Garimella reports no relevant disclosures.

Cooper ME, van Raalte DH. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025;135(21):e194749. doi:10.1172/JCI194749

GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD. HCPLive. Published July 30, 2026. Accessed July 31, 2026. 

https://www.hcplive.com/view/glp-1-receptor-agonists-reshape-ckd-treatment-sequencing-with-pranav-garimella-md

Videos

Pranav Garimella, MD, on how nephrologists and cardiologists can apply GLP-1 receptor agonist evidence to CKD treatment decisions.

Andrew Mastro, MS, PA-C, is a board-certified PA and guest lecturer at both Rush University and Northwestern University. 

In this episode, ‘Oral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides,’ the panelists, both practicing in dermatology, explore the evolving oral treatment landscape in plaque psoriasis. Andrew Mastro, MS, PA-C, shifts the conversation to the evolution of oral therapy in plaque psoriasis, asking Alexa Hetzel, MS, PA-C, how the market has changed as oral options have matured. Hetzel describes a field that has moved well beyond injectables-only, starting with PDE4 inhibitors that gave patients ineligible for biologics, such as those with a malignancy history, a viable systemic option, even if skin clearance lagged behind joint response. TYK2 inhibitors followed and delivered strong results in hand and foot psoriasis, though Hetzel notes that provider unfamiliarity with JAK-adjacent safety messaging limited uptake. Hetzel frames oral peptides like icotrokinra as the culmination of what clinicians have wanted from an oral agent: once-daily dosing, a formulation that can be dispersed in water, and efficacy that approaches what biologics deliver. Mastro agrees that biologic-like efficacy is a phrase that resonates with the clinicians he speaks with, and the two discuss how newer oral agents are resetting expectations for what an oral therapy can accomplish compared with injectable options. The discussion turns practical when Mastro raises adherence, noting that oral regimens can be uniquely challenging to sustain despite their convenience. Hetzel points out that many patients are already managing daily oral medications for other conditions, from blood pressure to thyroid disease, and that a shelf-stable, room-temperature oral therapy fits easily into an existing routine. For patients who travel for extended periods, an oral option can also solve access problems that make injectable dosing difficult. She adds that missed doses are a normal part of any regimen, oral or injectable, and that patients who occasionally miss a dose are not going to lose the ground they have gained, an assurance borne out by published randomized-withdrawal data on icotrokinra showing that response holds up well on continuous therapy and erodes only gradually after full discontinuation. Ultimately, Hetzel says the decision comes down to matching the regimen to what a given patient will actually be able to execute consistently. In the next episode, ‘Icotrokinra vs Deucravacitinib and Apremilast: Efficacy and Durability,’ the panelists weigh icotrokinra against deucravacitinib and apremilast on efficacy, safety, and durability of response.

Oral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides

In this episode, ‘Oral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides,’ the panelists, both practicing in dermatology, explore the evolving oral treatment landscape in plaque psoriasis.

Andrew Mastro, MS, PA-C, shifts the conversation to the evolution of oral therapy in plaque psoriasis, asking Alexa Hetzel, MS, PA-C, how the market has changed as oral options have matured. Hetzel describes a field that has moved well beyond injectables-only, starting with PDE4 inhibitors that gave patients ineligible for biologics, such as those with a malignancy history, a viable systemic option, even if skin clearance lagged behind joint response. TYK2 inhibitors followed and delivered strong results in hand and foot psoriasis, though Hetzel notes that provider unfamiliarity with JAK-adjacent safety messaging limited uptake.

Hetzel frames oral peptides like icotrokinra as the culmination of what clinicians have wanted from an oral agent: once-daily dosing, a formulation that can be dispersed in water, and efficacy that approaches what biologics deliver. Mastro agrees that biologic-like efficacy is a phrase that resonates with the clinicians he speaks with, and the two discuss how newer oral agents are resetting expectations for what an oral therapy can accomplish compared with injectable options.

The discussion turns practical when Mastro raises adherence, noting that oral regimens can be uniquely challenging to sustain despite their convenience. Hetzel points out that many patients are already managing daily oral medications for other conditions, from blood pressure to thyroid disease, and that a shelf-stable, room-temperature oral therapy fits easily into an existing routine. For patients who travel for extended periods, an oral option can also solve access problems that make injectable dosing difficult. She adds that missed doses are a normal part of any regimen, oral or injectable, and that patients who occasionally miss a dose are not going to lose the ground they have gained, an assurance borne out by published randomized-withdrawal data on icotrokinra showing that response holds up well on continuous therapy and erodes only gradually after full discontinuation. Ultimately, Hetzel says the decision comes down to matching the regimen to what a given patient will actually be able to execute consistently.

In the next episode, ‘Icotrokinra vs Deucravacitinib and Apremilast: Efficacy and Durability,’ the panelists weigh icotrokinra against deucravacitinib and apremilast on efficacy, safety, and durability of response.In the next episode, ‘Oral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides,’ Mastro and Hetzel trace how oral therapy evolved from PDE4 and TYK2 inhibition to once-daily oral peptides, and how that shift is changing conversations about adherence.

Trace how oral plaque psoriasis therapy has evolved over time, from PDE4 and TYK2 inhibition to once-daily oral peptides.

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Tapinarof cream (VTAMA) demonstrated consistent efficacy across pediatric and adult age groups.

Clinical improvements in eczema were observed as early as Week 2 and continued through Week 8.

Age-stratified analyses reinforce confidence in treating a heterogeneous atopic dermatitis population.

New analyses of the pivotal phase 3 ADORING 1 and ADORING 2 trials continue to strengthen the evidence supporting tapinarof cream, 1% (VTAMA) as a treatment option for 

 during the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting, Linda Stein Gold, MD, discussed findings from a post hoc analysis that, for the first time, examined efficacy outcomes separately among pediatric and adult age groups.

Age-Stratified Phase 3 Data Support Tapinarof Cream in Pediatric Eczema

Stein Gold explained that the analysis evaluated tapinarof cream, a nonsteroidal topical aryl hydrocarbon receptor (AhR) agonist approved for adults and pediatric patients aged 2 years and older with atopic dermatitis, across patients aged 2 years through adulthood. Although the original phase 3 program demonstrated overall efficacy, approximately 80% of enrolled participants were pediatric patients.

Separating the data by age allowed investigators to determine whether treatment effects remained consistent among younger children, adolescents, and adults. According to Stein Gold, the findings showed statistically significant improvements over vehicle in every age subgroup for key efficacy endpoints, reinforcing the consistency of the therapy's performance across a heterogeneous patient population.

Early Improvement May Support Long-Term Treatment Success

The pooled analysis demonstrated improvements with tapinarof cream as early as Week 2, with responses continuing through Week 8. By Week 8, significantly more patients receiving tapinarof achieved Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) success compared with vehicle across every age group.

This included children aged 2–6 years (56.3% vs 11.8%; 

= .0172), 12–17 years (48.8% vs 13.4%; 

= .0280). Similar statistically significant advantages were observed for EASI75 responses, with rates reaching 70.2% versus 20.5% among the youngest children and remaining consistently higher than vehicle across all other age groups.

Stein Gold noted that evaluating outcomes by age is clinically important because atopic dermatitis presents differently throughout life. Disease characteristics, treatment response, and tolerability may vary between toddlers, adolescents, and adults, making subgroup analyses particularly valuable for clinicians. She emphasized that the consistent efficacy observed across each cohort provides reassurance that tapinarof performs similarly despite the disease's heterogeneity.

Significance of Findings on Tapinarof Cream

Stein Gold also highlighted the practical significance of early improvement. Because atopic dermatitis is a chronic disease that often begins in infancy and can persist for years, rapid symptom relief may encourage patients and families to remain adherent to treatment.

From a clinician's perspective, seeing meaningful improvement within the first several weeks can reinforce confidence that therapy is working, helping support continued treatment and, ultimately, better long-term outcomes.

Disclosures for Stein Gold include AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults. Organon. July 24, 2026. Accessed July 31, 2026. 

https://www.organon.com/news/new-analysis-of-phase-3-pooled-data-for-organons-vtama-tapinarof-cream-1-demonstrates-early-consistent-improvements-in-atopic-dermatitis-patients-across-pediatric-age-groups-and-in/

Fonacier L, Boguniewicz M, Ohayon J, et al. Tapinarof cream 1% in atopic dermatitis: consistent efficacy across age groups from pooled ADORING trials. Poster presented at: Society for Pediatric Dermatology (SPD) Annual Meeting; July 23, 2026; Minneapolis, MN.

Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. 

New phase 3 data show tapinarof cream (VTAMA) delivered early, consistent efficacy across pediatric and adult age groups with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Multidisciplinary Care, Evidence-Based Practice in ILD: John Giacona, PhD

Explore why therapeutic inertia keeps plaque psoriasis patients cycling through topicals instead of escalating to systemic therapy.

Breaking the Topical Cycle in Plaque Psoriasis Management

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Atherosclerotic Cardiovascular Disease

Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial

As Palforzia exits the market on July 31, 2026, allergists Robert Wood, MD, and Jacqueline Ross, MD, outline what changes for patients already in treatment.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Palforzia Discontinued, Ending the Only FDA-Approved Peanut OIT Option

Lebrikizumab improved itch, quality of life, and infection rates in kids with moderate-to-severe atopic dermatitis, ADorable-1 results suggest.

What the ADorable-1 Trial Means for Pediatric Eczema Care

New phase 3 ADorable-1 data show lebrikizumab improved skin clearance in children with moderate-to-severe atopic dermatitis.

ADorable-1 Results: Key Findings in Pediatric Atopic Dermatitis

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

ACC Updates Expert Consensus Pathway for HFpEF Management

MV130, a sublingual mucosal trained immunity vaccine, showed significant benefits vs placebo, with benefit sustained after treatment ended.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

MV130 Mucosal Vaccine Reduces COPD Exacerbations in Phase 3 Trial

Benjamin van Boxtel, MD, is the surgical director at Atlantic Aortic Center and a cardiac surgeon with Atlantic Health.

Benjamin van Boxtel, MD, discusses the importance of familial screening for aortic dissection and the danger of missing potential risk factors.

Aortic Dissection: A Fatal Condition With an Underrepresented Genetic Risk

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

Latest News

Planetary Health Diet Reduces Risk of Cardiovascular Disease, CHD, Stroke, HF

Nerandomilast Reduces Mortality Risk in Pulmonary Fibrosis Analysis

GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy

Oral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides

Age-Stratified Phase 3 Data Support Tapinarof Cream in Pediatric Eczema